CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Disc Medicine dips after launching $350 stock offering

By Reuters News

** Disc Medicine's IRON.O shares down 1.5% to $77.77 in extended trading as it looks to raise equity

** Biopharma commences $350 mln offering comprising stock and pre-funded warrants

** IRON stock finished up 38.9% at $78.93 on Mon after its drug bitopertin met all main and secondary goals in late-stage study treatment for erythropoietic protoporphyria (EPP), a blood disorder which makes patients extremely sensitive to sunlight

** The late-stage success clears path for co to resubmit its application for an FDA review of bitopertin after the regulator turned down the drug earlier this year

** IRON to use the net offering proceeds to fund R&D of its current or additional product candidates, to support the potential commercialization of bitopertin for EPP and X-linked protoporphyria (XLP), among other purposes

** Jefferies, Leerink, Morgan Stanley and Cantor Fitzgerald joint bookrunners

** Watertown, Massachusetts-based IRON has ~38.4 mln shares outstanding for roughly $3 bln market cap

** All 13 analysts covering the stock are bullish; median PT $117.50, per LSEG data

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.